Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Benefit of Apabetalone on Plasma Proteins in Renal Disease.
Wasiak S, Tsujikawa LM, Halliday C, Stotz SC, Gilham D, Jahagirdar R, Kalantar-Zadeh K, Robson R, Sweeney M, Johansson JO, Wong NC, Kulikowski E. Wasiak S, et al. Among authors: johansson jo. Kidney Int Rep. 2017 Dec 8;3(3):711-721. doi: 10.1016/j.ekir.2017.12.001. eCollection 2018 May. Kidney Int Rep. 2017. PMID: 29854980 Free PMC article.
Apabetalone downregulates factors and pathways associated with vascular calcification.
Gilham D, Tsujikawa LM, Sarsons CD, Halliday C, Wasiak S, Stotz SC, Jahagirdar R, Sweeney M, Johansson JO, Wong NCW, Kalantar-Zadeh K, Kulikowski E. Gilham D, et al. Among authors: johansson jo. Atherosclerosis. 2019 Jan;280:75-84. doi: 10.1016/j.atherosclerosis.2018.11.002. Epub 2018 Nov 14. Atherosclerosis. 2019. PMID: 30476723 Free article.
Epigenetic Modulation by Apabetalone Counters Cytokine-Driven Acute Phase Response In Vitro, in Mice and in Patients with Cardiovascular Disease.
Wasiak S, Gilham D, Daze E, Tsujikawa LM, Halliday C, Stotz SC, Rakai BD, Fu L, Jahagirdar R, Sweeney M, Johansson JO, Wong NCW, Kulikowski E. Wasiak S, et al. Among authors: johansson jo. Cardiovasc Ther. 2020 Jul 21;2020:9397109. doi: 10.1155/2020/9397109. eCollection 2020. Cardiovasc Ther. 2020. PMID: 32821285 Free PMC article.
Inhibition of epigenetic reader proteins by apabetalone counters inflammation in activated innate immune cells from Fabry disease patients receiving enzyme replacement therapy.
Fu L, Wasiak S, Tsujikawa LM, Rakai BD, Stotz SC, Wong NCW, Johansson JO, Sweeney M, Mohan CM, Khan A, Kulikowski E. Fu L, et al. Among authors: johansson jo. Pharmacol Res Perspect. 2022 Jun;10(3):e00949. doi: 10.1002/prp2.949. Pharmacol Res Perspect. 2022. PMID: 35417091 Free PMC article.
Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism.
Tsujikawa LM, Fu L, Das S, Halliday C, Rakai BD, Stotz SC, Sarsons CD, Gilham D, Daze E, Wasiak S, Studer D, Rinker KD, Sweeney M, Johansson JO, Wong NCW, Kulikowski E. Tsujikawa LM, et al. Among authors: johansson jo. Clin Epigenetics. 2019 Jul 12;11(1):102. doi: 10.1186/s13148-019-0696-z. Clin Epigenetics. 2019. PMID: 31300040 Free PMC article.
Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial.
Ray KK, Nicholls SJ, Ginsberg HD, Johansson JO, Kalantar-Zadeh K, Kulikowski E, Toth PP, Wong N, Cummings JL, Sweeney M, Schwartz GG. Ray KK, et al. Among authors: johansson jo. Am Heart J. 2019 Nov;217:72-83. doi: 10.1016/j.ahj.2019.08.001. Epub 2019 Aug 9. Am Heart J. 2019. PMID: 31520897 Free article. Clinical Trial.
Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease.
Haarhaus M, Ray KK, Nicholls SJ, Schwartz GG, Kulikowski E, Johansson JO, Sweeney M, Halliday C, Lebioda K, Wong N, Brandenburg V, Beddhu S, Tonelli M, Zoccali C, Kalantar-Zadeh K. Haarhaus M, et al. Among authors: johansson jo. Atherosclerosis. 2019 Nov;290:59-65. doi: 10.1016/j.atherosclerosis.2019.09.002. Epub 2019 Sep 17. Atherosclerosis. 2019. PMID: 31568963 Free article.
Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial.
Ray KK, Nicholls SJ, Buhr KA, Ginsberg HN, Johansson JO, Kalantar-Zadeh K, Kulikowski E, Toth PP, Wong N, Sweeney M, Schwartz GG; BETonMACE Investigators and Committees. Ray KK, et al. Among authors: johansson jo. JAMA. 2020 Apr 28;323(16):1565-1573. doi: 10.1001/jama.2020.3308. JAMA. 2020. PMID: 32219359 Free PMC article. Clinical Trial.
BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes.
Wasiak S, Dzobo KE, Rakai BD, Kaiser Y, Versloot M, Bahjat M, Stotz SC, Fu L, Sweeney M, Johansson JO, Wong NCW, Stroes ESG, Kroon J, Kulikowski E. Wasiak S, et al. Among authors: johansson jo. Clin Epigenetics. 2020 Nov 11;12(1):166. doi: 10.1186/s13148-020-00943-0. Clin Epigenetics. 2020. PMID: 33172487 Free PMC article.
Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study.
Nicholls SJ, Schwartz GG, Buhr KA, Ginsberg HN, Johansson JO, Kalantar-Zadeh K, Kulikowski E, Toth PP, Wong N, Sweeney M, Ray KK; BETonMACE Investigators. Nicholls SJ, et al. Among authors: johansson jo. Cardiovasc Diabetol. 2021 Jan 7;20(1):13. doi: 10.1186/s12933-020-01199-x. Cardiovasc Diabetol. 2021. PMID: 33413345 Free PMC article. Clinical Trial.
107 results